Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Background Non‐small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR‐tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Upregulation of the receptor tyrosine kinase AXL in...

Full description

Bibliographic Details
Main Authors: Yoshikane Nonagase, Masayuki Takeda, Koichi Azuma, Hidetoshi Hayashi, Koji Haratani, Kaoru Tanaka, Kimio Yonesaka, Hidenobu Ishii, Tomoaki Hoshino, Kazuhiko Nakagawa
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Thoracic Cancer
Subjects:
AXL
EGFR‐TKI
GAS6
liquid biopsy and non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13166

Internet

https://doi.org/10.1111/1759-7714.13166

Similar Items